Our Company

Objectivity matters. Today, more than ever.

Independent for over 60 years, Milliman delivers market-leading services and solutions to clients worldwide. With no agenda, other than getting it right.

Through a team of professionals ranging from actuaries to clinicians, technology specialists to plan administrators, we offer unparalleled expertise in employee benefits, investment consulting, healthcare, life insurance and financial services, and property and casualty insurance.

News

See all news

Solutions

STAR Solutions - NAVI

Reduce risk calculation time and gain insight into risk exposure.

CORAL: A roadmap for ACA

CORAL helps you quickly estimate relative values of health benefit plans.

InvestMap

A sophisticated tool that enables DC plan sponsors to deploy an age-based, asset-allocation strategy.

Healthcare reform and hepatitis C: A convergence of risk and opportunity

  • Print
  • PDF
  • Connect
  • Email
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
By Bruce S. Pyenson, Kathryn V. Fitch, Kosuke Iwasaki, Tyler Engel | 19 December 2013
Changes from the Patient Protection and Affordable Care Act (ACA) are dominating the healthcare landscape. These changes under ACA are very important for people infected with hepatitis C virus (HCV). 2013 has seen increasing federal public health efforts aimed at diagnosing people with HCV. Baby boomers, the generation with the most HCV-infected people, has started to become eligible for Medicare. Further, new treatments for HCV are under development. Undiagnosed individuals and uninsured individuals may represent a population that payers and stakeholders have not yet experienced. This paper discusses how increased diagnosis, increased Medicare eligibility, and newly insured individuals with HCV will affect the U.S. healthcare system.